CoChat

JAK‐2 as a novel mediator of the profibrotic effects of transforming growth factor β in systemic sclerosis

Dees, Clara, Tomcik, Michal, Palumbo‐Zerr, Katrin, Distler, Alfiya, Beyer, Christian, Lang, Veronika, Horn, Angelika, Zerr, Pawel, Zwerina, Jochen, Gelse, Kolja, Distler, Oliver, Schett, Georg, Distler, Jörg H. W. · 2012 · Arthritis & Rheumatism
Cited by 148

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Objective: To investigate whether JAK‐2 contributes to the pathologic activation of fibroblasts in patients with systemic sclerosis (SSc) and to evaluate the antifibrotic potential of JAK‐2 inhibition for the treatment of SSc. Methods: Activation of JAK‐2 in human skin and in experimental fibrosis was determined by immunohistochemical analysis. JAK‐2 signaling was inhibited by the selective JAK‐2 inhibitor TG101209 or by small interfering RNA. Bleomycin‐induced dermal fibrosis in mice and TSK‐1 mice were used to evaluate the antifibrotic potential of specific JAK‐2 inhibition in vivo. Results: Increased activation of JAK‐2 was detected in the skin of patients with SSc, particularly in fibroblasts. The activation of JAK‐2 was dependent on transforming growth factor β (TGFβ) and persisted in cultured SSc fibroblasts. Inhibition of JAK‐2 reduced basal collagen synthesis selectively in SSc fibroblasts but not in resting healthy dermal fibroblasts. Moreover, inhibition of JAK‐2 prevented the stimulatory effects of TGFβ on fibroblasts. Treatment with TG101209 not only prevented bleomycin‐induced fibrosis but also effectively reduced skin fibrosis in TSK‐1 mice. Conclusion: We demonstrated that JAK‐2 is activated in a TGFβ‐dependent manner in SSc. Considering the potent antifibrotic effects of JAK‐2 inhibition, our study might have direct translational implications, because inhibitors of JAK‐2 are currently being evaluated in clinical trials for myeloproliferative disorders and would also be available for evaluation in patients with SSc.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.34500

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 148

Metadata

Authors
Dees, C., Tomcik, M., Palumbo‐Zerr, K., Distler, A., Beyer, C., Lang, V., Horn, A., Zerr, P., Zwerina, J., Gelse, K., Distler, O., Schett, G., & Distler, J. H. W.
Venue
Arthritis & Rheumatism
Publisher
Wiley
Published
2012-08-27
Volume
64
Issue
9
Pages
3006-3015
ISSN
  • 0004-3591 (ISSN-L)
  • 1529-0131
OpenAlex
W2108811339
Cited by
148
References
5
FWCI
4.99
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: JAK‐2 as a novel mediator of the profibrotic effects of transforming growth factor β in systemic sclerosis. https://app.cochat.ai/papers/10.1002/art.34500
The paper
Dees, C., Tomcik, M., Palumbo‐Zerr, K., Distler, A., Beyer, C., Lang, V., Horn, A., Zerr, P., Zwerina, J., Gelse, K., Distler, O., Schett, G., & Distler, J. H. W. (2012). JAK‐2 as a novel mediator of the profibrotic effects of transforming growth factor β in systemic sclerosis. Arthritis & Rheumatism. https://doi.org/10.1002/art.34500

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.